Download PDF
CC BY 4.0 · Glob Med Genet 2023; 10(04): 388-394
DOI: 10.1055/s-0043-1777789
Original Article

Integrative Analysis of PAIP2B to Identify a Novel Biomarker for Pancreatic Ductal Adenocarcinoma

Yaoxian Xiang
1   Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
,
Li Wang
1   Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
,
Yurong Cheng
1   Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
,
Huanjuan An
2   Department of Hematology, Peking University Shougang Hospital, Beijing, China
,
Chan Zhang
1   Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
,
Jing Wang
1   Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
,
Yingying Tong
1   Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
,
Dong Yan
1   Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
› Author Affiliations Funding This work was supported by the “R&D Program of Beijing Municipal Education Commission (KM202010025005),” “Beijing Municipal Natural Science Foundation (7222100),” and TongZhou District Science and Technology Plan Project (KJ2022CX021).
› Further Information
   Permissions and Reprints

Abstract

The aim of the study was to evaluate the potential diagnostic and prognostic value of gene, Poly A-Binding Protein Interacting Protein 2B (PAIP2B) in pancreatic cancer. We used the gene expression data and clinical information of pancreatic adenocarcinoma patients from The Cancer Genome Atlas database and Gene Expression Omnibus database to analyze the expression of PAIP2B in pancreatic cancer samples, and validated the expression of PAIP2B in tumor tissue, using bioinformatics technology to explore the prognostic value of PAIP2B and its possible biological function. A significantly lower level of PAIP2B was observed in pancreatic cancer patients than in controls, and validated by immunohistochemistry. PAIP2B reduced the proliferation and invasion of cancer cells and had a significantly high expression in early stage. Patients with lower levels of PAIP2B had a significantly shorter median survival time than those with higher levels. DNA demethylation played an important role in PAIP2B expression. In addition, PAIP2B expression was significantly associated with the tumor-infiltrating immune cells, especially T cells CD8, T cells CD4 memory resting, macrophages M0, and dendritic cells resting. Our study also found that PAIP2B regulated miRNA function leading to disease progression in pancreatic cancer patients. Our study explored the potential value of PAIP2B as a biological link between prognosis and pancreatic cancer, and provided reference for the follow-up study on the role of PAIP2B in pancreatic cancer.

Keywords

pancreatic carcinoma - PAIP2B - overall survival - prognosis - biomarker

Data Availability

The data underlying this article are available in TCGA database (https://tcga-data.nci.nih.gov/tcga/) and the GEO database (https://www.ncbi.nlm.nih.gov/geo/).


Authors' Contributions

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.


Supplementary Material



Publication History

Article published online:
19 December 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73 (01) 17-48
    CrossrefPubMedGoogle Scholar
  • 2 Jethwa KR, Sannapaneni S, Mullikin TC. et al. Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer. J Gastrointest Oncol 2020; 11 (06) 1408-1420
    CrossrefPubMedGoogle Scholar
  • 3 Grossberg AJ, Chu LC, Deig CR. et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020; 70 (05) 375-403
    CrossrefPubMedGoogle Scholar
  • 4 Tang H, Wei P, Chang P. et al. Genetic polymorphisms associated with pancreatic cancer survival: a genome-wide association study. Int J Cancer 2017; 141 (04) 678-686
    CrossrefPubMedGoogle Scholar
  • 5 Ivanov A, Shuvalova E, Egorova T. et al. Polyadenylate-binding protein-interacting proteins PAIP1 and PAIP2 affect translation termination. J Biol Chem 2019; 294 (21) 8630-8639
    CrossrefPubMedGoogle Scholar
  • 6 Khaleghpour K, Kahvejian A, De Crescenzo G. et al. Dual interactions of the translational repressor Paip2 with poly(A) binding protein. Mol Cell Biol 2001; 21 (15) 5200-5213
    CrossrefPubMedGoogle Scholar
  • 7 Mukherjee M, Goswami S. Identification of key deregulated RNA-binding proteins in pancreatic cancer by meta-analysis and prediction of their role as modulators of oncogenesis. Front Cell Dev Biol 2021; 9: 713852
    CrossrefPubMedGoogle Scholar
  • 8 Ritchie ME, Phipson B, Wu D. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43 (07) e47
    CrossrefPubMedGoogle Scholar
  • 9 Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012; 16 (05) 284-287
    CrossrefPubMedGoogle Scholar
  • 10 Szklarczyk D, Gable AL, Lyon D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019; 47 (D1): D607-D613
    CrossrefPubMedGoogle Scholar
  • 11 Shannon P, Markiel A, Ozier O. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13 (11) 2498-2504
    CrossrefPubMedGoogle Scholar
  • 12 Newman AM, Liu CL, Green MR. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015; 12 (05) 453-457
    CrossrefPubMedGoogle Scholar
  • 13 Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform 2021; 22 (06) bbab260
    CrossrefPubMedGoogle Scholar
  • 14 Gao Y, Shang S, Guo S. et al. Lnc2Cancer 3.0: an updated resource for experimentally supported lncRNA/circRNA cancer associations and web tools based on RNA-seq and scRNA-seq data. Nucleic Acids Res 2021; 49 (D1): D1251-D1258
    CrossrefPubMedGoogle Scholar
  • 15 Kolbeinsson HM, Chandana S, Wright GP, Chung M. pancreatic cancer: a review of current treatment and novel therapies. J Invest Surg 2023; 36 (01) 2129884
    CrossrefPubMedGoogle Scholar
  • 16 Bailey P, Chang DK, Nones K. et al; Australian Pancreatic Cancer Genome Initiative. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016; 531 (7592) 47-52
    CrossrefPubMedGoogle Scholar
  • 17 Dreyer SB, Upstill-Goddard R, Legrini A. et al; Glasgow Precision Oncology Laboratory, Australian Pancreatic Genome Initiative. Genomic and molecular analyses identify molecular subtypes of pancreatic cancer recurrence. Gastroenterology 2022; 162 (01) 320-324.e4
    CrossrefPubMedGoogle Scholar
  • 18 Wang C, Jiang X, Qi J, Xu J, Yang G, Mi C. PAIP2 is a potential diagnostic and prognostic biomarker of breast cancer and is associated with immune infiltration. Front Genet 2022; 13: 1009056
    CrossrefPubMedGoogle Scholar
  • 19 Berlanga JJ, Baass A, Sonenberg N. Regulation of poly(A) binding protein function in translation: characterization of the Paip2 homolog, Paip2B. RNA 2006; 12 (08) 1556-1568
    CrossrefPubMedGoogle Scholar
  • 20 Derry MC, Yanagiya A, Martineau Y, Sonenberg N. Regulation of poly(A)-binding protein through PABP-interacting proteins. Cold Spring Harb Symp Quant Biol 2006; 71: 537-543
    CrossrefPubMedGoogle Scholar
  • 21 Onesto C, Berra E, Grépin R, Pagès G. Poly(A)-binding protein-interacting protein 2, a strong regulator of vascular endothelial growth factor mRNA. J Biol Chem 2004; 279 (33) 34217-34226
    CrossrefPubMedGoogle Scholar
  • 22 Ezzeddine N, Chang TC, Zhu W. et al. Human TOB, an antiproliferative transcription factor, is a poly(A)-binding protein-dependent positive regulator of cytoplasmic mRNA deadenylation. Mol Cell Biol 2007; 27 (22) 7791-7801
    CrossrefPubMedGoogle Scholar
  • 23 Rouillard AD, Gundersen GW, Fernandez NF. et al. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database (Oxford) 2016; 2016: baw100
    CrossrefPubMedGoogle Scholar
  • 24 Kenney C, Kunst T, Webb S. et al. Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. Invest New Drugs 2021; 39 (03) 821-828
    CrossrefPubMedGoogle Scholar
  • 25 Yoshikawa T, Wu J, Otsuka M. et al. ROCK inhibition enhances microRNA function by promoting deadenylation of targeted mRNAs via increasing PAIP2 expression. Nucleic Acids Res 2015; 43 (15) 7577-7589
    CrossrefPubMedGoogle Scholar
  • 26 Fukao A, Aoyama T, Fujiwara T. The molecular mechanism of translational control via the communication between the microRNA pathway and RNA-binding proteins. RNA Biol 2015; 12 (09) 922-926
    CrossrefPubMedGoogle Scholar